New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 28, 2012
07:25 EDTNLNK, NLNKNewLink Genetics management to meet with Jefferies
Meeting to be held in San Francisco on January 4 hosted by Jefferies.
News For NLNK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 18, 2015
10:37 EDTNLNKOptions with decreasing implied volatility
Options with decreasing implied volatility: NLNK ARWR CTRP ZIOP CLNE ARIA VHC AOL KING XON PEIX
May 15, 2015
10:20 EDTNLNKOptions with decreasing implied volatility
Options with decreasing implied volatility: NLNK ARWR CTRP RAX KING AOL WPZ RL Z MBI
May 14, 2015
10:56 EDTNLNKOptions with decreasing implied volatility
Subscribe for More Information
May 13, 2015
11:08 EDTNLNKOptions with decreasing implied volatility
Subscribe for More Information
May 12, 2015
12:34 EDTNLNKOn The Fly: Top stock stories at midday
Subscribe for More Information
10:40 EDTNLNKNewLink Genetics weakness a buying opportunity, says Stifel
10:16 EDTNLNKOptions with decreasing implied volatility
Options with decreasing implied volatility: NDLS WTW FUEL AOL LC NLNK ZU CYBR ARWR HZNP
09:20 EDTNLNKOn The Fly: Pre-market Movers
Subscribe for More Information
08:04 EDTNLNKNewLink Genetics weakness not a buying opportunity, says Baird
Baird noted NewLink Genetics would continue its flagship IMPRESS trial as planned despite disclosing the FDA did not endorse management's plan to switch statistical methods midstream and the trial failed to show the required 30% OS improvement to stop early for efficacy. Baird expects the shares to open lower and would not be buyers, as they believe the chance of success of its algenpantucel-L trial has been lowered. Baird maintained its Neutral rating and $41 price target on NewLink Genetics shares.
May 11, 2015
19:15 EDTNLNKOn The Fly: After Hours Movers
Subscribe for More Information
16:42 EDTNLNKNewLink Genetics IMPRESS Phase 3 cancer trial with Algenpantucel-L to continue
NewLink Genetics announced the continuation without any modification or sample size adjustment for its pivotal, Phase 3 IMmunotherapy for Pancreatic RESectable cancer Study, called "IMPRESS," of algenpantucel-L for patients with surgically resected pancreatic cancer following the second planned interim data analysis. After careful consideration, including a series of communications with the FDA regarding the statistical analysis plan, the company decided to retain the benefit of the SPA and not to change the statistical analysis plan as defined in the original protocol. For the second interim analysis, the independent data safety monitoring committee, or DSMC, reviewed available patient data with the originally planned log-rank analysis and sample size recalculation, in all respects consistent with the SPA. No other statistical methods were used. The DSMC recommended the study proceed without any modifications, including sample size adjustment, to final analysis. Therefore the company believes the trial remains powered to determine efficacy upon the occurrence of 444 events.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use